Pathogenesis of atherosclerosis in diabetes and hypertension.
Prevalence of atherosclerotic vascular disease is markedly increased among individuals with diabetes-mellitus and hypertension. Its major clinical manifestations are consequences of atherosclerosis of coronary arteries, cerebral arteries and large arteries of lower extremities. Thus, atherosclerotic vascular disease is the major cause of mortality and significant morbidity in diabetes and hypertension. Dyslipidemia, hyperinsulinemia, and central obesity seem to be associated with increased risk of atherosclerosis, along with the development of hypertension and diabetes (NIDDM). Insulin resistance is the fundamental factor in this situation which has strong genetic predisposition. Accelerated atherosclerosis in diabetes due to mechanism unique to diabetes like non-enzymatic glycation of proteins, oxidative modification of lipoproteins, formation of lipoproteins immune complexes, lipoproteins aggregation, disturbances of cell replication and growth factors and propensity to thrombosis are clearly established. Therapeutic implication for the prevention of atherosclerosis in diabetes and hypertension clearly emphasizes the need to achieve tight control of hyperglycemia, hypertension, and hyperlipidemia in addition to avoiding cigarette smoking and developing obesity.
Shantaram
V
V
Department of Medicine, Nizam's Institute of Medical Sciences, Hyderabad, India.
D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology* / Q000473:pathology; D002455:Cell Division; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000473:pathology; D017127:Glycation End Products, Advanced / Q000097:blood; D006133:Growth Substances / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000473:pathology; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000473:pathology; D008074:Lipoproteins / Q000097:blood; D009765:Obesity / Q000097:blood / Q000150:complications; D012307:Risk Factors
D017127:Glycation End Products, Advanced; D006133:Growth Substances; D008074:Lipoproteins